ABSTRACT Studying HIV-infected individuals who control HIV replication (elite controllers [ECs]) enables exploration of effective anti-HIV immunity. HIV Env-specific and nonEnv-specific antibody-dependent cellular cytotoxicity (ADCC) may contribute to protection from progressive HIV infection, but the evidence is limited. We recruited 22 ECs and matched them with 44 viremic subjects. HIV Env-and Vpu-specific ADCC responses in sera were studied using a novel enzyme-linked immunosorbent assay (ELISA)-based dimeric recombinant soluble Fc␥RIIIa (rsFc␥RIIIa)-binding assay, surface plasmon resonance, antibody-dependent natural killer (NK) cell activation assays, and ADCC-mediated killing assays. ECs had higher levels of HIV Env-specific antibodies capable of binding Fc␥RIIIa, activating NK cells, and mediating granzyme B activity (all P Ͻ 0.01) than viremic subjects. ECs also had higher levels of antibodies against a C-terminal 13-mer Vpu peptide capable of mediating Fc␥RIIIa binding and NK cell activation than viremic subjects (both P Ͻ 0.05). Our data associate Env-specific and Vpu epitope-specific ADCC in effective immune responses against HIV among ECs. Our findings have implications for understanding the role of ADCC in HIV control.
and have repeatedly undetectable HIV plasma viremia in the absence of antiretroviral therapy (ART) (1) .
Numerous factors are likely involved in the control of HIV infection, including viral and host genetics, which cannot be easily manipulated in a broad-based vaccine or cure strategy. Particular HLA I alleles, such as HLA-B27, HLA-B57, and HLA-B51, are approximately twice as common in ECs as in people with progressive HIV infection (2) (3) (4) . HIV epitopes restricted by these alleles (especially targeting Gag) mediate potent HIV suppression (1, 5) . HIV-specific CD4 T-cell responses have higher functional avidities in ECs (6) , but somewhat counterintuitively, neutralizing antibodies (NAbs) are found less frequently in ECs than in viremic subjects (7, 8) . We previously reported that HIV-infected slow progressors have higher and broader antibody-dependent cellular cytotoxicity (ADCC) responses than people with progressive HIV (9, 10). Lambotte et al. have shown high HIV Env-specific ADCC responses in a heterogenous group of HIV controllers (11) . However, more data on the role of ADCC in elite control of HIV would facilitate the designing of strategies to control and prevent HIV.
Most antibody-related HIV vaccine research has focused on targeting the envelope (Env) protein of HIV. However, Env has proven to be a difficult target due to its wide diversity across the globe, its high mutation rate, and often poor access of NAbs to critical conserved epitopes (12, 13) . Since the partial efficacy seen in the RV144 trial and the results of the subsequent post hoc analyses, HIV-specific ADCC responses have gained importance as potential targets for prevention and control of infection (14) . These responses have several possible advantages over NAbs, in that they can target cells within which HIV is replicating and they can also target non-Env proteins such as Pol and Vpu (10, 15) .
In addition to Env, immune responses against the HIV regulatory transmembrane protein Vpu are of interest as potentially effective responses. We have previously identified HIV-specific NK cell activation by antibodies targeting the C-terminal portion of the Vpu protein and also showed that Vpu-specific ADCC responses were more common in subjects with slowly progressive HIV infection (16) . Chen et al. showed that polymorphisms in the terminal sequence of Vpu are associated with EC status compared with HIV viremic subjects, although the drivers of these polymorphisms were not identified, other than that they was independent of KIR2DL2 status (17) .
To investigate a potential role for ADCC in HIV control, we enrolled 22 ECs and compared these to a matched cohort of 44 viremic subjects and studied Env-and Vpu-specific ADCC responses.
RESULTS
ECs have high levels of total HIV Env-specific and Vpu-specific IgG antibodies compared to those of viremic subjects. ECs are a model to study HIV control (9, 18, 19) , and we recruited 22 ECs to provide serum samples and matched these subjects to 44 viremic subjects. The clinical characteristics of the subjects are shown in Tables 1 and  2 . Since functional antibody responses have been associated with the control of HIV in other settings, we studied antibody responses to both HIV Env and Vpu in ECs. Env is a common target for functional antibody responses (7), and we previously observed Vpu-specific functional antibody responses in a subset of HIV-infected subjects (10) . In the current study, we first analyzed total antibody responses and found that sera from 22 ECs had higher levels of HIV Env-specific IgG antibodies than those from the 44 matched viremic subjects (P Ͻ 0.0001) (Fig. 1A, left panel) . As a sensitivity analysis, we performed a conditional logistic regression test accounting for matching between cases and controls and observed a trend toward higher levels of Env-specific IgG in the ECs (adjusted P value [P=] ϭ 0.069). We also observed higher Vpu protein-specific IgG responses in the EC cohort (P ϭ 0.086 and P= ϭ 0.027) (Fig. 1A , middle panel). We had previously mapped an antibody response to the Vpu protein to a C-terminal 13-mer linear peptide (termed "Vpu19" since it is the 19th of 19 overlapping Vpu peptides previously studied) (20) . We found that ECs had significantly higher levels of Vpu19-specific antibodies than viremic subjects (P Ͻ 0.0001 and P= ϭ 0.002) (Fig. 1A, right  panel) .
Certain HLA I alleles, particularly HLA-B57, -B27, and -B51 play an important role in controlling HIV through CD8 ϩ T cells and are enriched in EC cohorts (3) . It has been postulated that ECs without protective HLA I alleles may be more enriched for non-CD8 T-cell responses capable of controlling HIV (21) . Six of the 20 ECs tested had one of these three beneficial HLA I alleles (Table 1) , and we therefore compared these 6 ECs to the other 14 ECs without beneficial HLA I alleles and to the viremic subjects for Env and Vpu antibody responses. We did not observe any overall difference in the binding antibodies against HIV Env and Vpu within the two EC subgroups, although there was a trend toward higher Vpu protein-specific antibody responses in the EC cohort without protective HLA I alleles (Fig. 1B, middle panel) . Furthermore, the subset of ECs without protective HLA I alleles continued to have significantly higher levels of binding antibodies against Vpu19 than viremic subjects (P Ͻ 0.05) (Fig. 1B, right panel) .
ECs have high levels of Fc␥RIIIa-binding antibodies to HIV Env and Vpu compared to those of viremic subjects. There is increasing interest in antibodies to HIV Env with Fc-mediated functions, although the protective importance of such (22) (23) (24) . We adapted this assay to study the ability of HIV-specific antibodies to bind higher-affinity dimeric rsFc␥RIIIa ( Fig. 2A ) and found that anti-HIV Env antibodies in the sera of ECs bound the dimeric rsFc␥RIIIa more potently than antibodies in the sera of viremic subjects (P Ͻ 0.0001 and P= ϭ 0.002) (Fig. 2B , left panel). Furthermore, there was a trend toward higher dimeric rsFc␥RIIIa binding for Vpu protein (P ϭ 0.073 and P= ϭ 0.010) (Fig. 2B , middle panel) in EC sera than in sera from viremic subjects. We also found that antibodies to the Vpu19 peptide in ECs bound the dimeric rsFc␥RIIIa more potently than those in viremic subjects' sera (P ϭ 0.036 and P= ϭ 0.014) (Fig. 2B, right panel) . When comparing protective-versus nonprotective-HLA-carrying ECs, we did not see any differences in the dimeric rsFc␥RIIIa-binding antibodies against HIV Env (Fig. 2C, left Fc␥R binding is influenced by several factors other than the amount of antibody, including IgG-Fc proximity, glycosylation, and antibody subtype. We surmised that the potency of dimeric rsFc␥RIIIa binding may be distinct from antibody concentration and therefore performed endpoint titrations using half-log dilutions of sera against the HIV Env in a subset of 10 ECs and their 20 matched viremic subjects. For the samples at a 1:10 dilution, a normalized optical density (OD) threshold of 0.455 for the dimeric rsFc␥RIIIa-binding activity almost evenly divided the viremic subjects into high-and low-FcR-activity groups (see the receiver operator curve [ROC] analysis in Materials and Methods). As previously (Fig. 2B) , most of the ECs had high FcR activity above this threshold (80%) (Fig. 2D) . Interestingly, however, endpoint titration showed similar total levels of Env-specific dimeric rsFc␥RIIIa-binding antibodies in ECs and viremic subjects (Fig. 2E ). The higher levels of Env-specific dimeric rsFc␥RIIIa-binding antibodies at low serum dilutions (1:10) despite similar overall titers may suggest greater breadth of epitope coverage in the ECs, consistent with our previous ADCC studies in slow progressors (9, 10) . Alternatively, this improved EC plasma binding to the rsFc␥RIIIa could suggest that EC plasma either binds gp140 more effectively or binds the rsFc␥RIIIa more effectively.
EC antibodies dissociate from gp140 more slowly than antibodies from viremic subjects. We postulated that the mechanism of improved gp140-specific binding to the rsFc␥RIIIa observed in the EC cohort could be through improved plasma antibody binding to gp140 and/or more effective binding to rsFc␥RIIIa. To evaluate these possibilities, we developed a novel surface plasmon resonance (SPR) assay using polyclonal IgG purified from plasma to study both interactions. Purified IgG from ECs or viremic subjects was first passed across and allowed to bind to AD8 Env-gp140 immobilized onto the SPR chip. Following partial dissociation of bound IgG from the antibody-Envgp140 complex, dimeric rsFc␥RIIIa was injected to probe the Fc␥RIIIa-binding activity of the Env-specific IgG. As it is not practical to isolate Env-specific IgG from the patient samples, we purified and quantitated the total IgG from the samples using "melon" affinity chromatography. Figure 3A shows an example of data form dilutions of EC and viremic subjects' IgG samples.
The complex polyclonal nature of the samples and the multivalent interactions of Env trimer with bivalent antibodies result in kinetics that cannot be strictly interpreted with simple defined binding models. Nonetheless, SPR analysis is highly informative, in particular, the dissociation rate (k d ), which is a concentration-independent measurement that can be examined quantitatively in polyclonal IgG preparations (25) . We observed that the rate of IgG binding to Env was slower for the ECs than for the viremic subjects (Fig. 3B) . However, since binding rates are related to analyte concentration, this could occur with lower concentrations of Env-specific IgG in the EC samples of total purified IgG and/or by a functional difference in recognition of Env protein by these antibodies.
FIG 2
ECs have higher levels of dimeric rsFc␥RIIIa-binding antibodies than viremic subjects, (A) Dimeric rsFc␥RIIIa-binding assay setup. HIV antigen (50 ng/well) was applied to a 96-well MaxiSorp plate, followed by addition of 1:10 diluted serum (containing IgGs). Subsequently, biotinylated dimeric rsFc␥RIIIa was added, binding between antibodies and dimeric rsFc␥RIIIa was measured using HRP-conjugated streptavidin and TMB, and reaction stopped with HCl. Absorbance was measured at 450 nm. (B) Dimeric rsFc␥RIIIa V158-binding antibodies detected in ECs (n ϭ 22) compared to those of viremic subjects (n ϭ 44) against HIV Env (left panel), Vpu protein (middle panel), and Vpu19 peptide (right panel) using a 1:10 serum dilution; for Env, the dotted line at OD ϭ 0.455 represent a cutoff of dimeric rsFc␥RIIIa-binding activity calculated using ROC analyses. All data were normalized to 5 g/ml HIV IgG immunoglobulin. Bars represent medians (P values from Mann-Whitney U test). However, of interest, the dissociation of the EC Env-specific IgG was slower than that of Env-specific IgG from the viremic subjects (median k d [1/s] ϭ 1.01 ϫ 10 Ϫ5 for ECs and 0.00131 for viremic subjects). This may have functional importance for the EC Envspecific IgG, possibly reflecting more stable prolonged opsonization of Env protein, thereby enhancing the opportunities for IgG to engage and activate Fc␥R-bearing cells.
When k a /k d values were plotted as a measure of the apparent binding activities, there was no apparent difference between the two cohorts. In addition, when binding of the dimeric rsFc␥RIIIa to Env-specific IgG complexes was examined, there was no apparent difference in the kinetics of binding to IgG from the ECs or the viremic subjects (Fig. 3C) .
Higher levels of antibody-mediated NK cell activation in ECs than in viremic subjects. In order to corroborate our finding using a dimeric rsFc␥RIIIa binding assay with a functional ADCC assay, we first performed antibody-mediated NK cell activation assays. This assay studies the ability of Env-or Vpu-specific antibodies to induce cytokine (gamma interferon [IFN-␥]) expression and/or degranulation (CD107a expression) in gated NK cells (9, 26) . We found that Env-specific antibodies in the sera of ECs induced a higher proportion of NK cells to express IFN-␥ and/or CD107a than those in and Fc␥RIIIa dimer binding activity to gp140-specific IgG that remained associated with the gp140 protein chip (C) were calculated using the BIAevaluation program, and differences between ECs and viremic subjects were measured using Mann-Whitney nonparametric t tests.
the sera of viremic subjects (P ϭ 0.0006 and P= ϭ 0.009) (Fig. 4A, left panel) . We also studied the capacity of Vpu19 peptide-specific antibodies to induce NK cell activation in both groups and that found sera from the ECs had higher levels than those from viremic subjects (P ϭ 0.005 and P= ϭ 0.014) (Fig. 4C, left panel) . When comparing the effect of protective-versus nonprotective-HLA-carrying ECs, there were no significant differences between these EC subgroups against either HIV Env (Fig. 4B) or the Vpu19 peptide (Fig. 4D) .
To dissect the ability of the antibodies to differentially stimulate killing functions through degranulation as represented by CD107a expression and cytokine secretion via IFN-␥ expression, we analyzed NK cell expression of IFN-␥ and CD107a against Env and Vpu19 separately in ECs compared to viremic subjects. We found significantly high IFN-␥ as well as CD107a expression by NK cells against Env stimulation in ECs compared to viremic subjects (Fig. 4A, middle and right panels) . We also found higher CD107a expression by NK cells against Vpu19 stimulation in ECs compared to viremic subjects (Fig. 4C, right panel) ; however, the Vpu19 antibody-stimulated IFN-␥ expression did not differ between the two groups (Fig. 4C, middle panel) .
In vitro ADCC-mediated killing is higher in ECs than in viremic subjects. Antibody clustering of Fc␥Rs and subsequent NK cell activation are necessary steps toward granzyme B delivery to HIV Env-expressing target cells. To more directly study antibody-mediated granzyme B delivery to target cells, we employed the ADCCGranToxiLux (ADCC-GTL) assay, which measures the entry of granzyme B into target cells as a surrogate of ADCC-mediated killing (27) . In the ADCC-GTL assay, we found that Env-specific antibodies in the sera of ECs induced a higher granzyme B activity than those in sera of viremic subjects (P ϭ 0.0074 and P= ϭ 0.014) (Fig. 5A) . When comparing the effect of protective-versus nonprotective-HLA-carrying ECs, there were no significant differences between these EC subgroups (Fig. 5B) .
The rapid fluorometric ADCC (RFADCC) assay is another antibody-mediated functional assay that measures the loss of integrity of Env-coated target cells by measuring the uptake of target cell membrane by monocytes (28) . Using the RFADCC assay, we observed only a weak trend toward increased uptake of Env-coated target cell membrane by gated monocytes (PKH26 ϩ CD3 Ϫ CD14 ϩ ) in the sera of ECs compared to those of viremic subjects (P ϭ 0.139 and P= ϭ 0.296) (Fig. 6A) . When comparing protective-versus nonprotective-HLA-carrying ECs, we did not see any difference in the killing within the two EC subgroups (Fig. 6B) .
DISCUSSION
The investigation of ECs, who naturally control HIV infection, may provide valuable insights into immune correlates of protection from disease progression. Several viral, genetic, and immunological factors are involved in HIV control (3, 17, (29) (30) (31) (32) . The role of HIV-specific ADCC is gaining prominence following post hoc analyses of the partially successful RV144 trial (33) (34) (35) . There is increasing evidence from studies in both humans and macaques that correlate robust ADCC responses with slow disease progression (9, 10, 36, 37) . ADCC responses have also been shown to develop rapidly following infection with HIV-1, which suggests that these responses could contribute to HIV control at the early stages of infection (38, 39) . We previously showed a role for ADCC in HIV control in viremic controllers (9, 10, 40) . However, data on the role for ADCC in ECs is limited. Lambotte et al. found that ECs had high levels of HIV Env-specific ADCC, whereas levels of NAbs were lower than those in viremic subjects (7) . More recently, Ackerman et al. found polyfunctional antibody effector activity in ECs but not enhanced antibody responses compared to those in viremic subjects (41) . Our data add weight to the concept that ADCC antibodies can assist durable suppression of HIV replication.
HIV Env is a key target for an effective antibody-based HIV vaccine, but its high genetic variability poses a large hurdle to vaccine design. Immune escape from broadly neutralizing antibodies that are directed against the surface-exposed parts of free virions is the norm (42) . We previously showed Env escape from ADCC, and it is possible that immune escape reduced our detection of Env ADCC in viremic subjects (16) . ECs may have less immune escape from ADCC responses, since there is so little virus replication and likely minimal evolution. Env-specific cytotoxic T lymphocytes (CTLs) are relatively less effective than Gag-specific CTL responses in controlling HIV (43, 44) . We studied HIV Env-specific ADCC antibody responses in ECs compared to viremic subjects and found that ECs have more potent Env-specific ADCC responses than viremic subjects. This is despite the fact that ECs have less antigenic stimulation through undetectable plasma viral loads (VLs). A potential limitation of our functional assays is that we studied Env protein-pulsed target cells, and further work studying ADCC on HIV-infected cells, as a more relevant target, is warranted.
The dimeric rsFc␥RIIIa ELISA-based assay to measure the binding of HIV-specific antibodies to Fc␥RIIIa is a relatively novel approach to studying functional antibodies for HIV, having previously been used to study influenza virus-specific antibodies (22) (23) (24) . Commonly used ADCC assays can be difficult to reproduce across laboratories due to variability of effector and target cells, and they are difficult to perform on a large scale. The ELISA-based assay using soluble dimeric rsFc␥RIIIa to detect the presence of HIV-specific ADCC antibodies in patient sera is robust and high throughput, and broadly consistent differences were observed between ECs and viremic subjects with the NK cell activation and ADCC killing assays. The dimeric rsFc␥RIIIa detects pairs of closely spaced IgGs, and such antibodies may comprise some of the opsonizing antibodies that effectively cross-link Fc␥RIIIa and induce NK cell activation. The assay is rapid and easy to perform and does not require use of effector cells. This assay may prove useful for high-throughput analyses of future vaccine trials.
Using the dimeric rsFc␥RIIIa ELISA-based assay, we found that EC sera had greater capacity for both IgG binding to Env protein and binding of the IgG-opsonized Env to the dimeric rsFc␥RIIIa, together suggesting a broader coverage of Env-specific epitopes in the B-cell response of the ECs. The lack of differences between endpoint titers of these antibodies in ECs compared to viremic subjects likely indicates that, although broader in epitope coverage, the EC Env-specific antibodies are not necessarily characterized by superior titer. This novel assay highlights that the quality of the antibody response with Fc-mediated function may be as important as or more important than the titer of the response. Future studies identifying conserved Env-specific ADCC epitopes commonly targeted by ECs could assist in designing improved HIV vaccines.
In addition, our SPR studies allowed us to examine the binding activity of Envspecific IgG from ECs and viremic subjects. The SPR data were fitted to the simplest 1:1 Langmuir binding model, but due to the polyclonal nature of patient IgG and the complexities of bivalent antibody binding to trimeric gp140 Env, this approach was only descriptive and not intended to be interpreted mechanistically. Nonetheless, the apparent dissociation rate, which is concentration independent, can be compared between samples. The significantly lower dissociation rates of Env-specific IgG of ECs suggest that these EC IgGs may have a prolonged ability to opsonize Env antigens, allowing for longer formation of immune complexes and increased opportunities for Fc␥R engagement activation of Fc␥R-bearing innate immune cells. Interestingly, we did not observe any intrinsic differences in the Fc␥R-binding activity of Env-specific IgG immune complexes by this SPR assay in the cohorts studied. However, highly functional forms of IgG have been identified in spontaneous HIV controllers, for example, enhanced levels of afucosylated IgG (45) and isotypes such as IgG3, which have a more flexible hinge region (41) , that can strongly enhance binding to Fc␥RIIIa and improve ADCC, which may not be apparent in these small quantities of bulk IgG.
We found Vpu-specific ADCC responses in ECs, consistent with our previous work on slow progressors (10) . HIV Vpu is a crucial viral transmembrane protein that serves two important functions to promote HIV replication inside the host: (i) CD4 degradation to evade immune recognition and (ii) virus release by antagonizing the host restriction factor tetherin (46, 47) . Tetherin is important for preventing HIV release and has more recently been shown to restrict cell-to-cell transmission of HIV (48, 49) . Recent studies have identified a major role for Vpu in limiting Env expression on the surface of HIV-infected cells. The ability of Vpu to inhibit tetherin expression on the surface of infected cells reduces the binding and recognition of ADCC antibodies and thereby may protect infected cells from ADCC (50) (51) (52) 62) . If ADCC antibody recognition of Vpu can disable Vpu-mediated tetherin inhibition, it would enhance the functionality of Env-specific ADCC antibodies and could significantly contribute to HIV control. In our IgG-ELISA and dimeric rsFc␥RIIIa ELISA-based assay, while screening the cohort using the whole purified Vpu protein we detected some ECs with ADCC antibody responses to whole Vpu protein but not to Vpu19 peptide. This suggests that some antibodies might be targeting an extracellular domain of Vpu that could interfere with interactions with tetherin, thereby counteracting the antagonistic effect of Vpu. The importance of immune targeting of Vpu has further been noted by Alter et al., who described mutations within Vpu that are linked to recognition of Vpu-expressing cells for direct killing by specific NK cell subsets (53) . The role of CTLs targeting Vpu has also been described previously (54) . Taken together, the data suggest that Vpu is a potentially useful target for anti-HIV immune responses. Ongoing work to generate and test the ADCC function of Vpu-specific monoclonal antibodies is under way. We acknowledge that our work on both Env-and Vpu-specific ADCC does not prove a causal link between ADCC and EC status. Interventional passive-transfer studies in macaques are suggestive of a role for ADCC function in addition to neutralization capacity in prevention and control of simian-human immunodeficiency virus (SHIV) infection (55, 56) , and further passive-transfer studies in macaques and humans should provide more definitive evidence.
In summary, elite control of HIV is a multifactorial phenomenon, and our findings suggest that ECs have strong ADCC responses to HIV Env and Vpu compared to those of viremic subjects. Prolonged binding of EC antibodies to Env may allow for the more effective engagement of Fc␥Rs. Novel targets for ADCC antibodies to conserved HIV antigens such as Vpu may be relevant to target HIV with preventative and therapeutic vaccines.
MATERIALS AND METHODS
Study cohort. The clinical characteristics of the 22 elite controllers (ECs) and 44 viremic subjects are shown in Table 1 . ECs were defined as having over 65% of the plasma HIV RNA measurements taken as below the detection limit in the absence of ART. An average of 88.6% of all viral loads (VLs) across ECs were below the limit of detection as determined by commercial HIV ϩ RNA assays used in practice at the time (VLs ranged from Ͻ400 copies/ml in past years to Ͻ20 copies/ml more recently). All subjects were followed for at least 3 months. Longitudinal data for all the ECs are collated in Table 2 . ECs (predominantly having HIV-1 subtype B) were recruited in Australia, both in Melbourne through the Melbourne Sexual Health Centre and Alfred Health (10 subjects) and in Sydney through Sydney LTNP cohort (12 subjects) (10). ECs were 1:2 case matched to the viremic subjects based on age (window of Ϯ5 years), gender, subtype of HIV, and duration of infection. This case-control matching design enables comparison of outcomes among ECs and viremic subjects while reducing bias due to confounding variables. The viremic subjects with VLs of Ͼ10,000 copies/ml were recruited from subjects enrolled in the ENCORE1 clinical trial of reduced-dose efavirenz (57, 58) . We studied 44 viremic subjects from baseline visit prior to initiation of ART (mean plasma HIV RNA of 5.1 log 10 copies/ml). Healthy HIV-negative volunteers provided the donor whole blood and peripheral blood mononuclear cells (PBMCs). Research was conducted under the auspices of the Alfred Human Health Research Ethics Committee for the Melbourne EC cohort, the St Vincent's Sydney Human Research Ethics Committee for the Sydney EC cohort, and participating institutional review boards at all recruiting sites for the ENCORE1 trial. effector cells at a 5:1 effector-to-target (E:T) cell ratio. The GFP-CD16 (176V) NK-92 cell line was kindly provided by Kerry Campbell from the Institute for Cancer Research in Philadelphia, PA. Twenty-five microliters of each effector and target cell suspension and 75 l of granzyme B substrate (OncoImmunin, Inc.) were dispensed into each well of a 96-well V-bottom plate. After incubation for 5 min at room temperature, a 1:1,000 dilution of sera was added and incubated for 15 min at room temperature. The plates were subsequently centrifuged for 1 min at 300 ϫ g and incubated for 1 h at 37°C and 5% CO 2 . After two washes with wash buffer, cells were resuspended in 50 l of wash buffer and placed at 4°C, and data were acquired with the LSRII flow cytometer (BD Bioscience, San Jose, CA) within 2 h. Data analysis was performed using FlowJo version 10.0.6 software. For all HIV Env responses, the SIV Env control responses (average of 4.8%) were subtracted. A positive response was defined as a percent granzyme B activity higher than three times the mean of the response to HIV Env using sera from five HIV-negative donors.
RFADCC assay. The rapid fluorometric ADCC (RFADCC) assay was used as previously described (28) . Briefly, 10 6 CEM.NKr-CCR5 cells were coated with 3 g of HIV Env and left for 1 h at room temperature. SIV Env-coated CEM.NKr-CCR5 cells were used as a control and were treated identically. Coated CEM.NKr-CCR5 cells were initially labeled with PKH26 (Sigma) and carboxyfluorescein succinimidyl ester (CFSE) (Sigma). PKH26 ϩ CFSE ϩ labeled CEM.NKr-CCR5 target cells (2 ϫ 10 4 ) were incubated with human sera (1:100 final dilution) for 30 min at 37°C, followed by addition of 2 ϫ 10 5 PBMCs (total volume of 100 l) to achieve an E:T cell ratio of 10:1. Cells were incubated for 4 h at 37°C and then stained with PerCP-conjugated anti-CD3 (clone SK7; BioLegend) and APC-H7-conjugated anti-CD14 (clone MP9; BD Biosciences) antibodies. Flow cytometry data were collected using a FACS LSR II flow cytometer (BD Biosciences). The data analysis was performed using FlowJo version 10.0.6 software and a gating strategy as previously described (28) . The assay readout is percentage of PKH26 ϩ CD3 Ϫ CD14 ϩ monocytes, which is the measure of CFSE Ϫ CD3 Ϫ CD14 ϩ monocytes that acquire the target cell PKH26 dye. For all HIV Env-specific responses, the SIV Env control responses (average of 5.7%) were subtracted. A positive response was defined as higher than three times the mean of the response to HIV Env using sera from five HIV-negative donors.
Statistical analysis. Statistical analyses were performed with GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA) and SPSS version 18 software (IBM, Armonk, NY). For comparisons between ECs and viremic subjects, an unadjusted P value was derived using nonparametric Mann-Whitney U tests (referred to here as the P value). As a sensitivity analysis, adjusted P values (P=) were derived using conditional logistic regression tests accounting for matching between cases and controls. The median was used to describe the data for Mann-Whitney U tests. For multiple comparisons in Fig. 1B, 2C , 3B, 4B, and 5B, Kruskal-Wallis tests were performed. A P value of Ͻ0.05 was considered to indicate a significant difference. Receiver operator curve (ROC) analysis was performed to establish the dimeric rsFc␥RIIIa-binding activity threshold (normalized OD ϭ 0.455) that best distinguished between the ECs and viremic subjects (data analyzed from Fig. 2B , left panel, area under the curve ϭ 81.9% and P Ͻ 0.0001).
